Edition:
India

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

76.73EUR
23 Aug 2019
Change (% chg)

€-0.29 (-0.38%)
Prev Close
€77.02
Open
€76.92
Day's High
€77.73
Day's Low
€76.52
Volume
1,823,197
Avg. Vol
2,421,830
52-wk High
€80.44
52-wk Low
€71.74

Latest Key Developments (Source: Significant Developments)

Sanofi - In July 2019, Sanofi U.S. Got Subpoena From NY AG's Office Regarding An Inquiry Related To Insulin Pricing
Monday, 29 Jul 2019 

July 29 (Reuters) - Sanofi SA ::SANOFI - IN JULY 2019, SANOFI U.S. GOT SUBPOENA FROM NEW YORK ATTORNEY GENERAL’S OFFICE IN CONNECTION WITH AN INQUIRY RELATED TO INSULIN PRICING.SANOFI - SUBPOENA SEEKS DOCUMENTS RELATING TO INSULIN PRODUCTS INCLUDING DOCUMENTS ABOUT PRICING, DISCOUNT PROGRAMS, OTHERS.SANOFI - SUBPOENA SEEKS DOCUMENTS RELATING TO INSULIN PRODUCTS INCLUDING ABOUT SALES & EXPENSES, CONTRACTING, MARKETING MATERIALS, LEGAL PROCEEDINGS.  Full Article

Sanofi Says Ends Partnership With Lexicon To Develop Diabetes Drug
Saturday, 27 Jul 2019 

July 27 (Reuters) - Sanofi SA ::SANOFI PROVIDES UPDATE ON ZYNQUISTATM (SOTAGLIFLOZIN) TYPE 2 DIABETES PHASE 3 PROGRAM AND COLLABORATION WITH LEXICON.SANOFI PROVIDED NOTICE TO LEXICON IT IS TERMINATING COLLABORATION TO DEVELOP ZYNQUISTA IN ALL ONGOING GLOBAL TYPE 1, TYPE 2 DIABETES PROGRAMS.AT THIS TIME, ONGOING PHASE 3 CLINICAL TRIALS WILL CONTINUE AND THERE WILL BE NO IMMEDIATE CHANGES.  Full Article

Opiant Pharmaceuticals Expands Partnership With Sanofi
Tuesday, 23 Jul 2019 

July 23 (Reuters) - Opiant Pharmaceuticals Inc ::OPIANT PHARMACEUTICALS EXPANDS PARTNERSHIP WITH SANOFI, SIGNS AGREEMENT FOR MANUFACTURING OPNT004 FOR TREATMENT OF ACUTE CANNABINOID OVERDOSE.OPIANT PHARMACEUTICALS INC - OPIANT INTENDS TO REFORMULATE DRINABANT FOR PARENTERAL ADMINISTRATION IN AN EMERGENCY DEPARTMENT SETTING.OPIANT - LICENSED EXCLUSIVE GLOBAL RIGHTS FROM SANOFI FOR DEVELOPMENT AND COMMERCIALIZATION OF DRINABANT FOR EMERGENCY TREATMENT OF ACO.OPIANT - MANUFACTURING WILL BE PERFORMED IN SANOFI ÚJPEST SITE (HUNGARY) ACTING AS A CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO).  Full Article

BIOCORP Enters Exclusive Negotiations With Sanofi
Wednesday, 3 Jul 2019 

July 3 (Reuters) - BIOCORP PRODUCTION SA ::BIOCORP ENTERS EXCLUSIVE NEGOTIATIONS WITH SANOFI TO USE THEIR MALLYATM CONNECTED DEVICE WITH SANOFI’S INTEGRATED DIABETES CARE PLATFORM.BIOCORP ENTERS EXCLUSIVE NEGOTIATIONS WITH SANOFI TO USE THEIR MALLYATM CONNECTED DEVICE WITH SANOFI’S INTEGRATED DIABETES CARE PLATFORM.BIOCORP TO RECEIVE UPFRONT PAYMENT OF 4 MEUR.UNDER TERMS OF THESE EXCLUSIVE NEGOTIATIONS, BIOCORP WILL GET AN INITIAL PAYMENT OF EUR 4 MILLION FROM SANOFI TO SUPPORT RELATED DEVELOPMENT ACTIVITIES.  Full Article

FDA Approves Dupixent (Dupilumab) For Chronic Rhinosinusitis With Nasal Polyposis
Wednesday, 26 Jun 2019 

June 26 (Reuters) - Regeneron Pharmaceuticals Inc ::FDA APPROVES DUPIXENT® (DUPILUMAB) FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS.FDA APPROVED DUPIXENT (DUPILUMAB) FOR USE WITH OTHER MEDICINES TO TREAT CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS.  Full Article

Voyager Therapeutics Announces Restructured Gene Therapy Relationship With Sanofi Genzyme
Monday, 17 Jun 2019 

June 17 (Reuters) - Voyager Therapeutics Inc ::VOYAGER THERAPEUTICS ANNOUNCES RESTRUCTURED GENE THERAPY RELATIONSHIP WITH SANOFI GENZYME AND PORTFOLIO UPDATE.VOYAGER THERAPEUTICS INC - GAINS WORLDWIDE RIGHTS TO VY-HTT01 FOR HUNTINGTON'S DISEASE.VOYAGER THERAPEUTICS INC - GAINS WORLDWIDE RIGHTS TO VY-HTT01 FOR HUNTINGTON'S DISEASE.VOYAGER THERAPEUTICS INC - RESOURCES TO BE REALLOCATED TO VY-HTT01 AND OTHER PROGRAMS; INTENDS TO SEEK A PARTNER FOR SOD1 ALS PROGRAM.VOYAGER THERAPEUTICS INC - RESOURCES TO BE REALLOCATED TO VY-HTT01 AND OTHER PROGRAMS; INTENDS TO SEEK A PARTNER FOR SOD1 ALS PROGRAM.VOYAGER THERAPEUTICS INC - NO LONGER EXPECTS TO FILE AN IND APPLICATION FOR VY-SOD102 IN 2019.VOYAGER THERAPEUTICS INC - IN CONSIDERATION OF RIGHTS RETURNED, VOYAGER HAS AGREED TO MAKE A $10 MILLION UPFRONT PAYMENT TO SANOFI GENZYME.VOYAGER THERAPEUTICS INC - SANOFI GENZYME OBTAINS EXCLUSIVE OPTION RIGHTS TO SELECT NOVEL AAV CAPSIDS OWNED OR CONTROLLED BY VOYAGER FOR EXCLUSIVE USE.VOYAGER THERAPEUTICS INC - AN ADDITIONAL $10 MILLION MILESTONE PAYMENT IS DUE TO SANOFI GENZYME.VOYAGER THERAPEUTICS INC - PRECLINICAL STUDIES ARE UNDERWAY WITH VY-HTT01.VOYAGER - SANOFI GENZYME'S OPTION TO ACQUIRE DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO A FUTURE VOYAGER CNS ORPHAN PROGRAM IS TERMINATED.VOYAGER THERAPEUTICS INC - VOYAGER INTENDS TO SEEK A PARTNER TO ADVANCE ITS PRECLINICAL PROGRAM FOR SOD1 ALS.VOYAGER THERAPEUTICS INC - VOYAGER NO LONGER EXPECTS TO FILE AN IND APPLICATION FOR VY-SOD102 IN 2019.  Full Article

Regeneron Announces Positive Early-Stage Data For REGN1979 In Patients With B-Cell Non-Hodgkin Lymphoma
Friday, 14 Jun 2019 

June 14 (Reuters) - Regeneron Pharmaceuticals Inc ::REGENERON CD20XCD3 BISPECIFIC REGN1979 SHOWS POSITIVE RESULTS IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA, INCLUDING IN CAR-T FAILURES.REGENERON PHARMACEUTICALS - IN THIS TRIAL, TWO PATIENTS WHO FAILED CAR-T THERAPY AND RECEIVED REGN1979 80 MG ACHIEVED COMPLETE RESPONSES.REGENERON PHARMACEUTICALS - 93% OVERALL RESPONSE & 71% COMPLETE RESPONSE RATES IN FOLLICULAR LYMPHOMA GRADES 1 TO 3A TREATED WITH REGN1979 5 MG-320 MG.  Full Article

Verily Forms Strategic Alliances With Novartis, Otsuka, Pfizer And Sanofi To Transform Clinical Research
Tuesday, 21 May 2019 

May 21 (Reuters) - Verily, Novartis, Otsuka, Pfizer And Sanofi::VERILY FORMS STRATEGIC ALLIANCES WITH NOVARTIS, OTSUKA, PFIZER AND SANOFI TO TRANSFORM CLINICAL RESEARCH.VERILY FORMS STRATEGIC ALLIANCES WITH NOVARTIS, OTSUKA, PFIZER AND SANOFI TO TRANSFORM CLINICAL RESEARCH.VERILY - BIOPHARMACEUTICAL ORGANIZATIONS JOIN PROJECT BASELINE INITIATIVE TO ENGAGE MORE PATIENTS AND CLINICIANS IN RESEARCH.  Full Article

Regeneron Announces Updated Libtayo Results In Advanced Cutaneous Squamous Cell Carcinoma
Thursday, 16 May 2019 

May 16 (Reuters) - Regeneron Pharmaceuticals Inc ::UPDATED LIBTAYO® (CEMIPLIMAB-RWLC) RESULTS REINFORCE DURABLE AND SUBSTANTIAL RESPONSE RATES IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA.REGENERON PHARMACEUTICALS INC - NEW DATA AT ASCO INCLUDE MORE THAN DOUBLE PATIENTS PREVIOUSLY REPORTED.REGENERON PHARMACEUTICALS INC - MEDIAN OVERALL SURVIVAL STILL NOT REACHED WITH A MEDIAN FOLLOW-UP OF UP TO 17 MONTHS IN STUDY.  Full Article

FDA Says Approval Of Dengvaxia Was Granted To Sanofi Pasteur
Thursday, 2 May 2019 

May 1 (Reuters) - U.S. FDA::FIRST FDA-APPROVED VACCINE FOR PREVENTION OF DENGUE DISEASE IN ENDEMIC REGIONS.FDA - APPROVAL OF DENGVAXIA WAS GRANTED TO SANOFI PASTEUR.FDA - APPROVAL OF DENGVAXIA, FOR PEOPLE AGED 9 THROUGH 16.  Full Article

Photo

EU approves Sanofi, Regeneron's Dupixent for adolescent eczema cases

PARIS The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won regulatory approval in Europe for moderate-to-severe cases of eczema in adolescents, the companies said.